Skip to main content
SpringerLink
Log in
Book cover

Patient Reported Outcome Measures in Rheumatic Diseases pp 357–370Cite as

PROMs for Polymyalgia Rheumatica

  • Chapter
  • First Online:

  • 816 Accesses

Abstract

Patient reported outcomes (PROs) are being increasingly recognized as important measures by rheumatologists. In this chapter, we review the use of PROs in published studies of patients with polymyalgia rheumatica (PMR) and the inclusion of these measures as part of diagnostic criteria and disease activity composite indices. In addition, an evaluation of the performance of a multidimensional health assessment questionnaire (MDHAQ) to document improvement in patients with PMR is presented.

Pain and morning stiffness are the most frequently used PROs in PMR, not only as part of diagnostic and classification criteria but also as part of the PMR activity score, a composite index to monitor disease activity. MDHAQ/RAPID3 is useful to evaluate improvement, similar to erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) to document effective response to prednisone. In general, PROs perform well in assessing disease activity in patients with PMR and may be useful to monitor patients in routine care and clinical trials. The MDHAQ can be a useful generic instrument for patients with PMR. Further work is needed to evaluate if other domains, not routinely collected and important for patients, need to be incorporated.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Cimmino MA, Zaccaria A. Epidemiology of polymyalgia rheumatica. Clin Exp Rheumatol. 2000;18(4 Suppl 20):S9–11.

    CAS  PubMed  Google Scholar 

  2. Proven A, Gabriel SE, O’Fallon WM, Hunder GG. Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis. J Rheumatol. 1999;26(6):1333–7.

    CAS  PubMed  Google Scholar 

  3. Gamez-Nava JI, Gonzalez-Lopez L, Davis P, Suarez-Almazor ME. Referral and diagnosis of common rheumatic diseases by primary care physicians. Br J Rheumatol. 1998;37(11):1215–9.

    Article  CAS  PubMed  Google Scholar 

  4. Narvaez J, Nolla-Sole JM, Clavaguera MT, Valverde-Garcia J, Roig-Escofet D. Longterm therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis. J Rheumatol. 1999;26(9):1945–52.

    CAS  PubMed  Google Scholar 

  5. Gabriel SE, Sunku J, Salvarani C, O’Fallon WM, Hunder GG. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 1997;40(10):1873–8.

    Article  CAS  PubMed  Google Scholar 

  6. Dasgupta B, Borg FA, Hassan N, Barraclough K, Bourke B, Fulcher J, Hollywood J, Hutchings A, Kyle V, Nott J, et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford). 2010;49(1):186–90.

    Article  Google Scholar 

  7. Matteson EL, Maradit-Kremers H, Cimmino MA, Schmidt WA, Schirmer M, Salvarani C, Bachta A, Dejaco C, Duftner C, Slott Jensen H, et al. Patient-reported outcomes in polymyalgia rheumatica. J Rheumatol. 2012;39(4):795–803.

    Article  PubMed  Google Scholar 

  8. Mackie SL, Arat S, da Silva J, Duarte C, Halliday S, Hughes R, Morris M, Pease CT, Sherman JW, Simon LS, et al. Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: outcomes of importance for patients with PMR. J Rheumatol. 2014;41(4):819–23.

    Article  PubMed  Google Scholar 

  9. Dejaco C, Duftner C, Cimmino MA, Dasgupta B, Salvarani C, Crowson CS, Maradit-Kremers H, Hutchings A, Matteson EL, Schirmer M, et al. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann Rheum Dis. 2011;70(3):447–53.

    Article  PubMed  Google Scholar 

  10. Huang A, Castrejon I: Patient-reported outcomes in trials of patients with polymyalgia rheumatica: a systematic literature review. Rheumatology international 2016. Jan 14. [Epub ahead of print].

    Google Scholar 

  11. Lund B, Egsmose C, Jorgensen S, Krogsgaard MR. Establishment of the relative antiinflammatory potency of deflazacort and prednisone in polymyalgia rheumatica. Calcif Tissue Int. 1987;41(6):316–20.

    Article  CAS  PubMed  Google Scholar 

  12. Di Munno O, Beghe F, Favini P, Di Giuseppe P, Pontrandolfo A, Occhipinti G, Pasero G. Prevention of glucocorticoid-induced osteopenia: effect of oral 25-hydroxyvitamin D and calcium. Clin Rheumatol. 1989;8(2):202–7.

    Article  PubMed  Google Scholar 

  13. Di Munno O, Imbimbo B, Mazzantini M, Milani S, Occhipinti G, Pasero G. Deflazacort versus methylprednisolone in polymyalgia rheumatica: clinical equivalence and relative antiinflammatory potency of different treatment regimens. J Rheumatol. 1995;22(8):1492–8.

    PubMed  Google Scholar 

  14. Krogsgaard MR, Lund B, Johnsson B. A long term prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica. J Rheumatol. 1995;22(9):1660–2.

    CAS  PubMed  Google Scholar 

  15. Salvarani C, Cantini F, Olivieri I, Barozzi L, Macchioni L, Boiardi L, Niccoli L, Padula A, Pulsatelli L, Meliconi R. Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study. J Rheumatol. 2000;27(6):1470–6.

    CAS  PubMed  Google Scholar 

  16. Kreiner F, Galbo H. Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. Arthritis Res Ther. 2010;12(5):R176.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Cimmino MA, Parodi M, Caporali R, Montecucco C. Is the course of steroid-treated polymyalgia rheumatica more severe in women? Ann N Y Acad Sci. 2006;1069:315–21.

    Article  CAS  PubMed  Google Scholar 

  18. Calvo L, Pistone G, Arnone S, Colomba D, Amico S, Giacalone A, Vitale P, Nicosia C, Barone E, Scaglione R, et al. Polymyalgia rheumatica and vertebral fractures: a 1-year pilot controlled study. Rheumatol Int. 2010;30(9):1245–7.

    Article  PubMed  Google Scholar 

  19. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982;9(5):789–93.

    CAS  PubMed  Google Scholar 

  20. Pincus T, Summey JA, Soraci Jr SA, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum. 1983;26(11):1346–53.

    Article  CAS  PubMed  Google Scholar 

  21. McHorney CA, Ware Jr JE, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32(1):40–66.

    Article  CAS  PubMed  Google Scholar 

  22. Bird HA, Leeb BF, Montecucco CM, Misiuniene N, Nesher G, Pai S, Pease C, Rovensky J, Rozman B. A comparison of the sensitivity of diagnostic criteria for polymyalgia rheumatica. Ann Rheum Dis. 2005;64(4):626–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C, Bachta A, Dejaco C, Duftner C, Jensen HS, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012;71(4):484–92.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Mackie SL, Hughes R, Walsh M, Day J, Newton M, Pease C, Kirwan J, Morris M. “An impediment to living life”: why and how should we measure stiffness in polymyalgia rheumatica? PLoS One. 2015;10(5), e0126758.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Dasgupta B, Salvarani C, Schirmer M, Crowson CS, Maradit-Kremers H, Hutchings A, Matteson EL, members of the American College of Rheumatology Work Group for Development of Classification Criteria for PMR. Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. J Rheumatol. 2008;35(2):270–7.

    PubMed  Google Scholar 

  26. Leeb BF, Bird HA, Nesher G, Andel I, Hueber W, Logar D, Montecucco CM, Rovensky J, Sautner J, Sonnenblick M. EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT). Ann Rheum Dis. 2003;62(12):1189–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica. Ann Rheum Dis. 2004;63(10):1279–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Cantini F, Salvarani C, Olivieri I, Macchioni L, Ranzi A, Niccoli L, Padula A, Boiardi L. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum. 2000;30(1):17–24.

    Article  CAS  PubMed  Google Scholar 

  29. Castrejon I, Huang A, Everakes SL, Nika A, Sequeira W, Pincus T. Documentation of clinical improvement in patient with polymyalgia rheumatica according to MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data): a longitudinal analysis from routine care. Arthritis Rheum. 2015;67 Suppl 10.

    Google Scholar 

  30. Pincus T, Sokka T, Kautiainen H. Further development of a physical function scale on a MDHAQ [corrected] for standard care of patients with rheumatic diseases. J Rheumatol. 2005;32(8):1432–9.

    PubMed  Google Scholar 

  31. Castrejon I, Bergman MJ, Pincus T. MDHAQ/RAPID3 to recognize improvement over 2 months in usual care of patients with osteoarthritis, systemic lupus erythematosus, spondyloarthropathy, and gout, as well as rheumatoid arthritis. J Clin Rheumatol. 2013;19(4):169–74.

    Article  PubMed  Google Scholar 

  32. van Tuyl LH, Boers M. Patient-reported outcomes in core domain sets for rheumatic diseases. Nat Rev Rheumatol. 2015;11(12):705–12.

    Article  PubMed  Google Scholar 

  33. Wells G, Li T, Maxwell L, Maclean R, Tugwell P. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis. 2008;67(2):260–5.

    Article  CAS  PubMed  Google Scholar 

  34. Castrejon I, Pincus T. Patient self-report outcomes to guide a treat-to-target strategy in clinical trials and usual clinical care of rheumatoid arthritis. Clin Exp Rheumatol. 2012;30 Suppl 73:S50–5.

    PubMed  Google Scholar 

  35. Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis. 1979;38(5):434–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Jones JG, Hazleman BL. Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis. 1981;40(1):1–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med. 1982;97(5):672–80.

    Article  CAS  PubMed  Google Scholar 

  38. Nobunaga M, Yoshioka K, Yasuda M, Shingu M. Clinical studies of polymyalgia rheumatica. A proposal of diagnostic criteria. Jpn J Med. 1989;28(4):452–6.

    Article  CAS  PubMed  Google Scholar 

  39. White DK, Wilson JC, Keysor JJ. Measures of adult general functional status: SF-36 Physical Functioning Subscale (PF-10), Health Assessment Questionnaire (HAQ), Modified Health Assessment Questionnaire (MHAQ), Katz Index of Independence in activities of daily living, Functional Independence Measure (FIM), and Osteoarthritis-Function-Computer Adaptive Test (OA-Function-CAT). Arthritis Care Res. 2011;63 Suppl 11:S297–307.

    Article  Google Scholar 

  40. Kalke S, Mukerjee D, Dasgupta B. A study of the health assessment questionnaire to evaluate functional status in polymyalgia rheumatica. Rheumatology (Oxford). 2000;39(8):883–5.

    Article  CAS  Google Scholar 

  41. Hutchings A, Hollywood J, Lamping DL, Pease CT, Chakravarty K, Silverman B, Choy EH, Scott DG, Hazleman BL, Bourke B, et al. Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum. 2007;57(5):803–9.

    Article  PubMed  Google Scholar 

  42. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984;27(8):864–72.

    Article  CAS  PubMed  Google Scholar 

  43. Sokka T, Hakkinen A, Krishnan E, Hannonen P. Similar prediction of mortality by the health assessment questionnaire in patients with rheumatoid arthritis and the general population. Ann Rheum Dis. 2004;63(5):494–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Castrejon I, Yazici Y, Samuels J, Luta G, Pincus T. Discordance of global estimates by patients and their physicians in usual care of many rheumatic diseases: association with 5 scores on a Multidimensional Health Assessment Questionnaire (MDHAQ) that are not found on the Health Assessment Questionnaire (HAQ). Arthritis Care Res. 2014;66(6):934–42.

    Article  Google Scholar 

  45. Starfield B, Wray C, Hess K, Gross R, Birk PS, D’Lugoff BC. The influence of patient-practitioner agreement on outcome of care. Am J Public Health. 1981;71(2):127–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Dasgupta B, Panayi GS. Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol. 1990;29(6):456–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Rush University Medical Center, Chicago, IL, USA

    Isabel Castrejon M.D., Ph.D.

Authors
  1. Isabel Castrejon M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Isabel Castrejon M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Honorary Senior Clinical Lecturer, King’s College London, London, United Kingdom

    Yasser El Miedany

Appendix 1: MDHAQ

Appendix 1: MDHAQ

figure afigure a

© Health Report Services. Reprinted with permission

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Castrejon, I. (2016). PROMs for Polymyalgia Rheumatica. In: El Miedany, Y. (eds) Patient Reported Outcome Measures in Rheumatic Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-32851-5_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-32851-5_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-32849-2

  • Online ISBN: 978-3-319-32851-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation